Ascendis Pharma A (ASND) Debt to Equity (2021 - 2025)

Ascendis Pharma A has disclosed Debt to Equity across 5 years of filings, most recently posting -$3.94 for Q4 2025.

• Debt to Equity for Q4 2025 came in at -$3.94, up 19.25% year-over-year; the trailing twelve-month figure through Dec 2025 was -$3.94 (up 19.25% YoY), and the FY2025 annual result was -$3.94, up 19.25% from the prior year.
• Debt to Equity came in at -$3.94 for Q4 2025 at Ascendis Pharma A, up from -$4.88 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $2.07 in Q4 2022 to a low of -$4.88 in Q4 2024.
• The 5-year median for Debt to Equity is $0.12 (2021), against an average of -$1.24.
• Across the five-year window, Debt to Equity jumped 1643.87% in 2022 and tumbled 221.37% in 2023, its largest moves.
• Ascendis Pharma A's Debt to Equity stood at $0.12 in 2021, then soared by 1643.87% to $2.07 in 2022, then sank by 221.37% to -$2.51 in 2023, then sank by 94.07% to -$4.88 in 2024, then advanced by 19.25% to -$3.94 in 2025.
• The last three Debt to Equity figures came in at -$3.94 (Q4 2025), -$4.88 (Q4 2024), and -$2.51 (Q4 2023), per Business Quant data.